Array
(
[1603241910] => Array
(
[wordfence_batchReportFailedAttempts] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1603241923] => Array
(
[wordfence_batchReportBlockedAttempts] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1603241932] => Array
(
[wordfence_processAttackData] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1603243614] => Array
(
[wordfence_hourly_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1603243926] => Array
(
[wp_update_themes] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_update_plugins] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1603244373] => Array
(
[wp_privacy_delete_old_export_files] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1603244881] => Array
(
[wpm_update_stats] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1603247353] => Array
(
[wp_version_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1603250273] => Array
(
[wp_session_garbage_collection] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1603261485] => Array
(
[recovery_mode_clean_expired_keys] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603261490] => Array
(
[wp_site_health_scheduled_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => weekly
[args] => Array
(
)
[interval] => 604800
)
)
)
[1603264112] => Array
(
[ai1wm_storage_cleanup] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603270171] => Array
(
[wp_scheduled_auto_draft_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603275311] => Array
(
[delete_expired_transients] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603275352] => Array
(
[wpseo-reindex-links] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603276014] => Array
(
[wordfence_daily_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603287874] => Array
(
[wp_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603296424] => Array
(
[akismet_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603299411] => Array
(
[yoast_tracking] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603461000] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[ac3606b3e32df31849103d61634f83d9] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1603461000
)
)
)
)
[1603720200] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[aa2113713b3cd2a2c03461011ed71376] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1603720200
)
)
)
)
[1603720800] => Array
(
[wordfence_email_activity_report] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
)
Etiquetas: 08/12/2011, 8 diciembre 2011, AC, Alemania, CCP, Certificado complementario de protección para un medicamento, Deutsches Patent und Markenamt, Fosfato de sitagliptina monohidrato, Januvia, Medicamentos con obligatoriedad de presentar datos pediátricos, Merck & Co. Inc, MERCK SHARP DOHME, Patente, Plazo de la prórroga pediátrica, Prórroga pediátrica, salud, Sanidad, Sentencia.
Etiquetas: 2007, Acción analgésica, Acido Acetilsalicílico, Almirall, Antirreumática, BRISTOL MYERS SQUIBB, CINFA, Consejo general de Cólegios oficiales de farmacéuticos, Enalapril, ESTEVE, Ibuprofeno, Importe, Laboratorios, Lorazepan, Madrid, medicamentos, Medicamentos sujetos a precios de referencia, Mercado de las Estatinas, Mercado de los medicamentos, Mercado de Medicamentos no sujetos a precios de referencia, Mercado de Medicamentos sujetos a precios de referencia, Mercado total de Medicamentos del Sistema Nacional de Salud, MERCK SHARP DOHME, Metamizol, Metformina, NOVARTIS FARMACEUTICA, Omeprazol, Paracetamol, PARKE DAVIS, Pfizer, Precio, Presentaciones, principios activos, Principios activos en el mercado de conjuntos y en el total del SNS, PVP, RATIOPHARM, salud, Sanidad, Simvastatina y Atorvastatina, Sistema Nacional de Salud, SNS, SOLVAY PHARMA, Ventas, Ventas por laboratorios, Ventas por presentaciones de los medicamentos, Ventas por principios activos.
.gif)